Mode
Text Size
Log in / Sign up
N/A Completed N=130 Diagnostic

Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects

Source: ClinicalTrials.gov NCT02603666 ↗
Enrolled (actual)
130
Serious AEs
0.0%
Results posted
Dec 2016
Primary outcomePrimary: Elastographic Value in kPa Measured by Fibroscan — 4.7 kPa

Summary

The aim of the study is to find CF patients at risk for cystic fibrosis related liver disease (CFLD). Comparison of ultrasound by two modalities and biochemical markers with histological evaluation of liver biopsy if present.

Outcome Measures

OutcomeResultp-value
PRIMARY
Elastographic Value in kPa Measured by Fibroscan
4.7

Eligibility Criteria

Inclusion Criteria

  • Verified cystic fibrosis

Exclusion Criteria

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02603666). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search